Viking Therapeutics, INC. (VKTX) — 10-Q Filings

10-Q Filings (6)

• Viking's R&D Surge Drives 171% Net Loss Increase to $202M — Oct 23, 2025 Risk: high
  Viking Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $201.977 million, a substantial ris
• Viking Therapeutics' Losses Widen Amid R&D Surge, Cash Position Strong — Jul 23, 2025 Risk: medium
  Viking Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage biotechnology status. The com
• Viking Therapeutics Files Q1 2025 10-Q — Apr 24, 2025 Risk: medium
  Viking Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and results of operations, includ
• Viking Therapeutics Files Q3 2024 10-Q — Oct 23, 2024 Risk: medium
  Viking Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and results of operations, in
• Viking Therapeutics Files Q2 2024 10-Q — Jul 24, 2024 Risk: medium
  Viking Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial position and operational highlights. Key financ
• Viking Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — Apr 25, 2024 Risk: medium
  Viking Therapeutics, Inc. (VKTX) filed a Quarterly Report (10-Q) with the SEC on April 25, 2024. Viking Therapeutics, Inc. filed a 10-Q report for the quarter e

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX